US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
JPH0395163A
(ja)
|
1989-09-08 |
1991-04-19 |
Daicel Chem Ind Ltd |
2.2.4.4.6―ペンタメチル―2.3.4.5―テトラヒドロピリミジンの製造法
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
EP0859841B1
(fr)
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Banques de proteines/(poly)peptides
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
CA2385769A1
(fr)
|
1999-09-17 |
2001-03-22 |
Gavin C. Hirst |
Inhibiteurs de kinase utilises comme agents therapeutiques
|
AU1560802A
(en)
|
2000-06-28 |
2002-01-08 |
Smithkline Beecham Plc |
Wet milling process
|
IL157898A0
(en)
|
2001-04-06 |
2004-03-28 |
Wyeth Corp |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
GB0221697D0
(en)
|
2002-09-18 |
2002-10-30 |
Unilever Plc |
Novel compouds and their uses
|
AU2003272175A1
(en)
|
2002-10-21 |
2004-05-04 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2004065416A2
(fr)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Banques de phages anticorps synthetiques
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
ATE399538T1
(de)
|
2003-03-26 |
2008-07-15 |
Egalet As |
Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
|
KR20120090094A
(ko)
|
2003-06-13 |
2012-08-16 |
바이오겐 아이덱 엠에이 인코포레이티드 |
아글리코실 항-cd154(cd40 리간드) 항체 및 이의 용도
|
CA2536408A1
(fr)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
|
US20050203063A1
(en)
|
2003-09-12 |
2005-09-15 |
Raymond Deshaies |
Proteasome pathway inhibitors and related methods
|
MY143225A
(en)
|
2004-04-02 |
2011-03-31 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
RU2007123675A
(ru)
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
RS51843B
(en)
|
2005-11-17 |
2012-02-29 |
Osi Pharmaceuticals Llc. |
CONDENSED BICYCLIC m TOR INHIBITORS
|
BRPI0619146A2
(pt)
|
2005-12-02 |
2011-09-13 |
Bayer Pharmaceuticals Corp |
derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
LT2474545T
(lt)
|
2005-12-13 |
2017-02-27 |
Incyte Holdings Corporation |
Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
|
JP5400388B2
(ja)
|
2005-12-15 |
2014-01-29 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
キナーゼインヒビターおよびその利用
|
ATE542823T1
(de)
|
2006-04-12 |
2012-02-15 |
Vertex Pharma |
4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
JP2009536161A
(ja)
|
2006-04-25 |
2009-10-08 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
ATE528002T1
(de)
|
2006-05-19 |
2011-10-15 |
Bayer Pharma AG |
Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
|
WO2008045978A1
(fr)
|
2006-10-10 |
2008-04-17 |
Rigel Pharmaceuticals, Inc. |
Dérivés de pyrimidinediamine substitués par du pinane, utiles en tant qu'inhibiteurs de axl
|
AU2007334379B2
(en)
|
2006-12-14 |
2013-04-18 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinase inhibitors
|
PL2078010T3
(pl)
|
2006-12-29 |
2014-07-31 |
Rigel Pharmaceuticals Inc |
Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
|
WO2008083354A1
(fr)
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
Triazoles substitués par n3-hétéroaryle et triazoles substitués par n5-hétéroaryle utiles comme inhibiteurs de axl
|
CA2710043C
(fr)
|
2006-12-29 |
2016-02-09 |
Rigel Pharmaceuticals, Inc. |
Triazoles a substitution aryle bicycliques et heteroaryle bicycliques utiles en tant qu'inhibiteurs axl
|
WO2008098139A2
(fr)
|
2007-02-07 |
2008-08-14 |
The Regents Of The University Of Colorado |
Inhibiteurs des récepteurs axl à activité tyrosine kinase et procédés de fabrication et d'utilisation de ceux-ci
|
KR20100014629A
(ko)
|
2007-03-29 |
2010-02-10 |
파나세아 바이오테크 리미티드 |
타크로리무스의 변형제형
|
MX2009013565A
(es)
|
2007-06-12 |
2010-06-02 |
Concert Pharmaceuticals Inc |
Derivados de azapeptidos.
|
CA2695753A1
(fr)
|
2007-08-15 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Composes utilises comme inhibiteurs de proteines kinases
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
KR20100089090A
(ko)
|
2007-10-25 |
2010-08-11 |
아스트라제네카 아베 |
세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
|
SI2205592T1
(sl)
|
2007-10-26 |
2013-09-30 |
Rigel Pharmaceuticals, Inc. |
Triazoli substituirani s policikličnim arilom in triazoli substituirani s policikličnim heteroarilom uporabni kot Axl inhibitorji
|
JP5537439B2
(ja)
|
2007-12-19 |
2014-07-02 |
アムジエン・インコーポレーテツド |
細胞周期阻害剤としての縮合ピリジン、ピリミジンおよびトリアジン化合物
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
CN102131783A
(zh)
|
2008-04-16 |
2011-07-20 |
马克斯普朗克科学发展组织 |
作为axl激酶抑制剂的喹啉衍生物
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
AU2009271658B2
(en)
|
2008-06-23 |
2014-04-10 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors
|
WO2010005879A1
(fr)
|
2008-07-09 |
2010-01-14 |
Rigel Pharmaceuticals, Inc. |
Triazoles substitués par hétéroaryle bicycliques pontés utiles comme inhibiteurs de axl
|
JP5592884B2
(ja)
|
2008-07-09 |
2014-09-17 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Axl阻害剤として有用な多環式ヘテロアリール置換トリアゾール
|
WO2010014755A1
(fr)
|
2008-07-29 |
2010-02-04 |
The Regents Of The University Of Colorado |
Procédés et composés permettant d’optimiser le traitement contre le cancer
|
EP2158913A1
(fr)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
US20100075973A1
(en)
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
WO2010071885A1
(fr)
|
2008-12-19 |
2010-06-24 |
Cephalon, Inc. |
Pyrrolotriazines en tant qu'inhibiteurs d'alk et de jak2
|
EP2393814A1
(fr)
|
2009-02-09 |
2011-12-14 |
SuperGen, Inc. |
Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
|
JP5656976B2
(ja)
|
2009-04-29 |
2015-01-21 |
ローカス ファーマシューティカルズ インコーポレイテッド |
ピロロトリアジン化合物
|
BRPI1012159B1
(pt)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
ME01838B
(me)
|
2009-06-29 |
2014-12-20 |
Lncyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
RU2012116526A
(ru)
|
2009-09-25 |
2013-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
|
EP2311809A1
(fr)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
AR079529A1
(es)
|
2009-12-18 |
2012-02-01 |
Incyte Corp |
Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
|
KR20220015492A
(ko)
|
2010-03-10 |
2022-02-08 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
WO2011123493A1
(fr)
|
2010-03-31 |
2011-10-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazines substituées à titre d'inhibiteurs de protéines kinases
|
CA2761074A1
(fr)
|
2010-05-05 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrimidines 4-substituees pouvant etre employees en tant qu'inhibiteurs de pkc-theta
|
EP2423208A1
(fr)
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
|
BR112013008526A2
(pt)
|
2010-10-08 |
2016-07-12 |
Elan Pharm Inc |
inibidores de quinase do tipo polo
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
CA2818542A1
(fr)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
|
EP2655374B1
(fr)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
|
AU2012223639B2
(en)
|
2011-02-28 |
2015-03-19 |
Sunshine Lake Pharma Co., Ltd. |
Substituted quinoline compounds and methods of use
|
EP2937349B1
(fr)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et flt3
|
EP2693881B1
(fr)
|
2011-04-01 |
2019-09-04 |
University of Utah Research Foundation |
Analogues de n-phénylpyrimidine-2-amine substitués en tant qu'inhibiteurs de l'axl kinase
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
EP2721028B1
(fr)
|
2011-06-20 |
2015-11-04 |
Incyte Corporation |
Dérivés d'azétidinyl-phényl-, de pyridyl- ou de pyrazinyl-carboxamide en tant qu'inhibiteurs des jak
|
PE20140570A1
(es)
|
2011-07-01 |
2014-04-28 |
Bayer Ip Gmbh |
Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
KR102371532B1
(ko)
|
2011-09-02 |
2022-03-07 |
인사이트 홀딩스 코포레이션 |
Pi3k 억제제로서 헤테로시클릴아민
|
DK2758052T3
(en)
|
2011-09-18 |
2018-05-28 |
Euro Celtique Sa |
Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
ES2650630T3
(es)
|
2011-10-03 |
2018-01-19 |
The University Of North Carolina At Chapel Hill |
Compuestos de pirrolopirimidina para el tratamiento del cáncer
|
PL2780338T3
(pl)
|
2011-11-14 |
2017-04-28 |
Ignyta, Inc. |
Pochodne uracylu jako inhibitory kinaz AXL i c-MET
|
AP2014007662A0
(en)
|
2011-11-29 |
2014-05-31 |
Perosphere Inc |
Anticoagulant reversal agents
|
WO2013085802A1
(fr)
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus
|
MY165215A
(en)
|
2012-01-31 |
2018-03-09 |
Daiichi Sankyo Co Ltd |
Pyridone derivatives
|
ES2581065T3
(es)
|
2012-02-23 |
2016-08-31 |
Bayer Intellectual Property Gmbh |
Benzotienil-pirrolotriazinas sustituidas y usos de las mismas
|
WO2013162061A1
(fr)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
Composé de pyrimidine bicyclique
|
WO2013173720A1
(fr)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Dérivés de pyrrolopyridine et de pyrrolopyrimidine substitués par un pipéridinylcyclobutyle à titre d'inhibiteurs jak
|
AU2013312477B2
(en)
|
2012-09-06 |
2018-05-31 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
WO2014062774A1
(fr)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Composés pyrazolopyrimidines pour le traitement du cancer
|
NZ707495A
(en)
|
2012-11-01 |
2019-01-25 |
Incyte Holdings Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
US9925193B2
(en)
|
2012-11-20 |
2018-03-27 |
Proqinase Gmbh |
Thioether derivatives as protein kinase inhibitors
|
WO2014109858A1
(fr)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
|
TW201522337A
(zh)
|
2013-03-12 |
2015-06-16 |
Arqule Inc |
經取代之三環吡唑並-嘧啶化合物類
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
ES2685661T3
(es)
|
2013-11-08 |
2018-10-10 |
Ono Pharmaceutical Co., Ltd. |
Derivado de pirrolopirimidina
|
AU2015225745B2
(en)
|
2014-02-03 |
2017-04-20 |
Cadila Healthcare Limited |
Heterocyclic compounds
|
GB201420285D0
(en)
|
2014-11-14 |
2014-12-31 |
Bergenbio As |
Process
|
EP3233829B1
(fr)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
|
WO2016183071A1
(fr)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Composés hétéro-tricycliques substitués et utilisation de ces composés pour le traitement du cancer
|
SI3456346T1
(sl)
|
2015-07-30 |
2021-11-30 |
Macrogenics, Inc. |
Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh
|
WO2017027717A1
(fr)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Composés de pyrimidine fusionnés bicycliques utilisés en tant qu'inhibiteurs de tam
|
WO2017035366A1
(fr)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
|
WO2017062797A1
(fr)
|
2015-10-07 |
2017-04-13 |
The University Of North Carolina At Chapel Hill |
Méthodes de traitement de tumeurs
|
JP6488402B2
(ja)
|
2015-10-13 |
2019-03-20 |
日本農薬株式会社 |
オキシム基を有する縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
|
JP6921818B2
(ja)
|
2015-11-14 |
2021-08-18 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
置換キノリン化合物の結晶形およびその医薬組成物
|
EP3373934B1
(fr)
|
2015-11-14 |
2020-05-20 |
Sunshine Lake Pharma Co., Ltd. |
Forme cristalline d'un composé de quinoléine substitué et compositions pharmaceutiques en contenant
|
FI3436461T3
(fi)
|
2016-03-28 |
2024-01-16 |
Incyte Corp |
Pyrrolotriatsiiniyhdisteitä tam-inhibiittoreina
|
WO2017184934A1
(fr)
|
2016-04-22 |
2017-10-26 |
Incyte Corporation |
Formulations d'un inhibiteur de lsd1
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
IL308256A
(en)
|
2016-07-15 |
2024-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
JOP20190257A1
(ar)
|
2017-04-28 |
2019-10-28 |
Novartis Ag |
مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
|
GEP20227429B
(en)
|
2017-09-27 |
2022-10-25 |
Incyte Corp |
Salts of pyrrolotriazine derivatives useful as tam inhibitors
|
US11241438B2
(en)
|
2018-06-29 |
2022-02-08 |
Incyte Corporation |
Formulations of an AXL/MER inhibitor
|
EP4114401A1
(fr)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1
|